Intestinal mTOR regulates GLP-1 production in mouse L cells

Diabetologia

Volumn 58, Issue 8, 2015, Pages 1887-1897

  Xu, Geyang ^a   Li, Ziru ^b   Ding, Li ^b   Tang, Hong ^b   Guo, Song ^a   Liang, Hongbin ^a   Wang, Huadong ^a   Zhang, Weizhen ^b,c  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b Shenzhen University School of Medicine   (China)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Blood glucose; Enteroendocrine L cells; GLP 1; Intestine; mTOR; Neurogenin 3

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NEUROGENIN 3; PROGLUCAGON; PROTEIN S6; RAPAMYCIN; TUBERIN; TUBEROUS SCLEROSIS 1 PROTEIN; UNCLASSIFIED DRUG; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOWN REGULATION; ENZYME IMMUNOASSAY; GENE DELETION; GLUCOSE INTAKE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; IMMUNOFLUORESCENCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; L CELL LINE; LIPID DIET; MALE; MOUSE; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENTEROENDOCRINE CELL; EXPERIMENTAL DIABETES MELLITUS; INTESTINE; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DOWN-REGULATION; ENTEROENDOCRINE CELLS; FASTING; GLUCAGON-LIKE PEPTIDE 1; INTESTINES; LEUCINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROGLUCAGON; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84937522354     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3632-6     Document Type: Article

References (42)

1. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157
2. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880–11889
3. Drucker DJ, Mojsov S, Habener JF (1986) Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. J Biol Chem 261:9637–9643
4. Philippe J, Mojsov S, Drucker DJ, Habener JF (1986) Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. Endocrinology 119:2833–2839
5. Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63–74
6. Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719–2725
7. Jin T, Drucker DJ (1995) The proglucagon gene upstream enhancer contains positive and negative domains important for tissue specific proglucagon gene transcription. Mol Endocrinol 9:1306–1320
8. Jin T (2008) Mechanisms underlying proglucagon gene expression. J Endocrinol 198:17–28
9. Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 280:1457–1464
10. Mansour A, Hosseini S, Larijani B, Pajouhi M, Mohajeri-Tehrani MR (2013) Nutrients related to GLP-1 secretory responses. Nutrition 29:813–820
11. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294:1102–1105
12. Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19–24
13. Um SH, Frigerio F, Watanabe M et al (2007) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205
14. Yang Q, Guan KL (2007) Expanding mTOR signaling. Cell Res 17:666–681
15. Xu G, Li Y, An W et al (2009) Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake. Endocrinology 150:3637–3644
16. Xu G, Wang Z, Li Y et al (2012) Ghrelin contributes to derangements of glucose metabolism induced by rapamycin in mice. Diabetologia 55:1813–1823
17. Li Z, Xu G, Li Y, Zhao J, Mulholland MW, Zhang W (2012) mTOR-dependent modulation of gastric nesfatin-1/NUCB2. Cell Physiol Biochem 29:493–500
18. Li Z, Gao L, Tang H et al (2013) Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS One 8, e71513
19. Li D, Han L, Li Y, Zhao J, He P, Zhang W (2014) Neurogenin 3–directed Cre deletion of Tsc1 gene causes pancreatic acinar carcinoma. Neoplasia 16:909–917
20. Lee YC, Asa SL, Drucker DJ (1992) Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem 267:10705–10708
21. Mortensen K, Christensen LL, Holst JJ, Orskov C (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189–196
22. Eissele R, Göke R, Willemer S et al (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Investig 22:283–291
23. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety–effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214
24. Schonhoff SE, Giel-Moloney M, Leiter AB (2004) Minireview: development and differentiation of gut endocrine cells. Endocrinology 145:2639–2644
25. Fraenkel M, Ketzinel-Gilad M, Ariav Y et al (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945–957
26. Barlow AD, Nicholson ML, Herbert TP (2013) Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes 62:2674–2682
27. Yang J, Dolinger M, Ritaccio G et al (2012) Leucine stimulates insulin secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of rapamycin) pathway: implication in new-onset diabetes in renal transplantation. J Biol Chem 287:24795–24806
28. Fuhrmann A, Lopes P, Sereno J et al (2014) Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol 88:216–228
29. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36:741–744
30. Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39–47
31. Kolterman OG, Buse JB, Fineman MS et al (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082–3089
32. Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW (2012) Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 97:121–131
33. Bjerre Knudsen L, Madsen LW, Andersen S et al (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473–1486
34. Parks M, Rosebraugh C (2010) Weighing risks and benefits of liraglutide–the FDA’s review of a new antidiabetic therapy. N Engl J Med 9:774–777
35. Deacon CF, Johnsen AH, Host JJ (2002) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957
36. Knudsen LB, Pridal L (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429–435
37. Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35:992–1019
38. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638–2643
39. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, de Williams-Herman (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632–2637
40. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156
41. Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58:1604–1615
42. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604